Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis.

British journal of clinical pharmacology·2026
Same author

Development of Motion Detection Algorithm Using 3d Sensors for Patient Monitoring Support Service System.

Studies in health technology and informatics·2025
Same author

Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant.

Clinical and translational science·2024
Same author

Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis.

Journal of drugs in dermatology : JDD·2023
Same author

Clinical Efficacy of Pre-Hospital Electrocardiogram Transmission in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.

International heart journal·2023
Same author

Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?

Clinical pharmacology in drug development·2021

Related Experiment Video

Updated: May 20, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by

Tomohisa Saito1, Satofumi Iida, Takehiko Kawanishi

  • 1Research Planning Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. saitotmh@chugaipharm.co.jp

Drug Metabolism and Pharmacokinetics
|July 13, 2012
PubMed
Summary

Peg-interferon-alpha-2a (PEG-IFN) treatment for chronic hepatitis C may cause a temporary platelet decrease. Modeling shows platelet counts typically recover within weeks, allowing safer use in patients with liver cirrhosis.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Related Experiment Videos

Last Updated: May 20, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Area of Science:

  • Pharmacology
  • Hepatology
  • Mathematical Modeling

Background:

  • Peg-interferon-alpha-2a (PEG-IFN) is a standard treatment for chronic hepatitis C (CHC).
  • PEG-IFN can decrease platelet counts, posing a risk for CHC patients with compensated liver cirrhosis who already have low baseline platelets.

Purpose of the Study:

  • To analyze the effect of PEG-IFN on platelet counts in CHC patients with compensated liver cirrhosis.
  • To develop a pharmacokinetic-pharmacodynamic model to predict longitudinal platelet profiles during PEG-IFN therapy.
  • To assess the safety of PEG-IFN administration in this patient population.

Main Methods:

  • Analysis of platelet count and serum PEG-IFN concentration data from 40 Japanese CHC patients.
  • Pharmacokinetic modeling using an open 1-compartment model for serum PEG-IFN.
  • Pharmacodynamic modeling using a turnover model for platelet counts.
  • Simulation of platelet profiles with various baseline levels.

Main Results:

  • PEG-IFN administration led to a gradual decrease in platelet counts, reaching a steady state within 12 weeks.
  • Simulations indicated that most patients would not experience platelet counts below treatment discontinuation criteria.
  • Platelet counts recovered to baseline levels within 4 to 8 weeks after PEG-IFN discontinuation.

Conclusions:

  • PEG-IFN treatment is predicted to cause a moderate platelet decrease (estimated 30% reduction).
  • The developed model suggests PEG-IFN can be used more safely in CHC patients with compensated liver cirrhosis.
  • Platelet recovery post-treatment is generally rapid, supporting the continued use of PEG-IFN.